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Abstract
Background: Chemotherapy induced peripheral neuropathy (CIPN) has been attributed to chemotherapeutic agents
such as cisplatin which adversely affect disease outcome leading to increased cancer related morbidity. The clinical
efficacy of systemic gabapentin in neuropathic pain management is limited by central side-effects in addition to a
scarceness of conclusive evidence of its efficacy in CIPN management. The topical route therefore may provide a
relatively safe alternative for neuropathic pain treatment in general and CIPN in particular.
Methods: Cisplatin induced neuropathic nociception was established in rats after a single weekly cisplatin
injection (3.0 mg/kg, intraperitoneally) for 4 weeks. The evoked neuropathic sensation of allodynia was
assessed by plantar application of von Frey monofilaments as the paw withdrawal threshold (PWT), whereas
the expression of heat-hypoalgesia was determined on a hot-plate as paw withdrawal latency (PWL).
Gabapentin gel (10% w/w) was applied three-times daily on the hind paws while in a concurrent systemic
study, gabapentin was administered daily (75 mg/kg, intraperitoneally) for 4 weeks. To assess any evidence of
neurological adverse symptoms of cisplatin and the central side-effect propensity of systemic or topical
gabapentin, evaluation of motor coordination (rotarod test) and gait (footprint analysis) were performed.
Results: Cisplatin invoked a progressive development of neuropathic hind paw allodynia (decreased PWT, days 7–28)
and heat hypoalgesia (increased PWL, days 21–28). Topical gabapentin significantly delayed the expression of both
allodynia on protocol days 21 and 28 and heat-hypoalgesia (day 28). Systemic gabapentin displayed a comparative
anti-neuropathic predisposition through a sustained suppression of tactile allodynia on days 14 and 21–28 as well as
thermal hypoalgesia (days 21 and 28). Systemic gabapentin also impaired motor coordination and gait thus affirming
its clinically documented central side effects, but these outcomes were not evident after topical treatment.
Conclusions: Both topical and systemic gabapentin exhibit a propensity to attenuate CIPN in a cisplatin paradigm.
Gabapentin applied topically may therefore provide an adjunctive or alternative route for CIPN management upon
cessation of systemic medications due to intolerable side-effects.
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Background
Chemotherapy induced peripheral neuropathy (CIPN) is
a frequent pathological complication in patients under-
going cancer treatment. This condition involves sensory
symptoms typically in the hands and feet and may
include pain, numbness or tingling and motor symptoms
expressed as weakness. It not only affects the patient’s
response to treatment due to the need for dose reduc-
tion or discontinuation, but also there may well be a
long term disruption of quality of life [1]. The prevalence
of CIPN differs with regard to the type of chemothera-
peutic agent used (72.3% with oxaliplatin, 42.2% with
cisplatin, 70.8% with paclitaxel, 19.6% with vincristine,
63.5% with thalidomide, and 46.7% with bortezomib),
and the duration of chemotherapy (68.1% in the first
month, 60.0% at 3 months and 30.0% at 6 months) [2].
Additionally, the presence of CIPN causes gait distur-
bances and may increase the risk of falls in cancer
patients undergoing chemotherapy [3, 4].
Cisplatin is a platinum-based drug which is highly
effective against various types of cancers, including
carcinomas, germ cell tumors, sarcomas and lymphomas
[5]. In addition, cisplatin has established the highest cure
rates in the management of testicular cancers (90%) [6, 7].
Although cisplatin has been considered a mainstay
treatment for cancer, its use is restricted by the induction
of resistance to its beneficial effects in cancer cells and the
occurrence of side-effects including nausea and vomiting,
neurotoxicity, ototoxicity, and renal injury [6, 8–11]. Many
patients completing a full course of cisplatin chemother-
apy develop a clinically detectable sensory neuropathy.
These symptoms include unpleasant distal paresthesias
(tingling in the extremities) and numbness that may occur
as soon as a month after initiating treatment, Lhermitte’s
symptom (an electric shock-like sensation on bending the
neck), indicating the involvement of the centripetal branch
of the sensory pathway within the spinal cord, large fiber
sensory loss (reduced vibration and joint position
sensations) and diminished or absent muscle stretch re-
flexes, sensory ataxia (incoordination) and mildly dimin-
ished small fiber sensation (decreased pin-pain sensation).
These neuropathic symptoms are a major reason for the
premature discontinuation of cisplatin and limitation of
its cumulative dosage, thereby potentially reducing its
chemotherapeutic efficacy [12].
The pharmacotherapy of systemic disorders including
peripheral neuropathy is a challenging task for clinicians
as well as biomedical scientists and recently, various
therapeutic moieties have been investigated for their
beneficial effects in neuropathic pain [13–19]. Different
treatment modalities have been devised for platinum
induced neuropathy which includes neuroprotective
agents, antidepressants and anticonvulsants [1, 12, 20].
Despite these preventive and therapeutic strategies,
treatment modification and drug withdrawal remain the
most effective modalities for a majority of patients with
CIPN. However, further preclinical and clinical research
is needed to establish better alternative options [20]. The
gabapentinoid, gabapentin has been one of the first line
drugs used in clinical practice for the treatment of
patients with established neuropathy. Preclinical studies
have demonstrated that gabapentin is able to attenuate
both the positive and negative neuropathic symptoms of
CIPN [15, 21]. However, there is conflicting evidence of
gabapentin efficacy in clinical trials, with some studies
showing a meaningful reduction in pain scores in
patients [22, 23], while others have obtained negative
results [24, 25]. Irrespective of these observations, gaba-
pentin has been considered a common choice of
clinicians to manage the positive symptoms associated
with CIPN [26, 27]. However, the therapeutic efficacy of
anti-neuropathic doses of gabapentin is greatly hindered
by side-effects such as dizziness, somnolence, ataxia,
weight gain, lethargy, and convulsions [28–31]. The
occurrence of side-effects along with therapy specific
precautions and contraindications has limited the
clinical analgesic utility of the current pharmacological
treatments and only < 50% of neuropathic patients
actually show any improvement in their pain states [30].
There is a recent trend for targeting the peripheral
nervous system in neuropathic pain and from this per-
spective, various topical agents have been compounded
and successfully tested in patients and various animal
models [32–34]. Nociceptors in layers of the skin contain
various types of receptor that bind different ligands which
influence the generation of pain transmitting action
potentials. Topical formulations traverse epidermal tissue
and increase the nociceptive threshold by stabilizing the
membranes of specific nociceptors [35]. The topical route
presents distinct advantages because there is low systemic
clearance, minimum chance of drug interaction, relative
patient tolerability and the feasibility of combination with
various oral medications [36]. A variety of topical prepara-
tions have been investigated in CIPN. These include a
baclofen with amitriptyline plus ketamine organogel
(BAK) combination [37], low-concentration menthol [38,
39], phenytoin [40], an amitriptyline and ketamine cream
[41] and topical combinations of α2-adrenergic receptor
agonists or nitric oxide (NO) donors combined with either
phosphodiesterase (PDE) or phosphatidic acid (PA)
inhibitors [42].
Considering the beneficial anti-neuropathic profile
of systemic gabapentin, its central side-effect tendency
and the inconsistency of its effectiveness in CIPN,
this study investigated the possible efficacy of a gaba-
pentin (10%) topical gel formulation in a refined
CIPN rat model of peripheral neuropathic pain. Previ-
ously, this gel has been reported to alleviate both
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mechanical allodynia and vulvodynia in an animal
model of streptozotocin-induced diabetic neuropathic
nociception [33] and in the traumatic nerve injury
model of neuropathic allodynia and hyperalgesia [43].
Methods
Chemicals
Topical gabapentin as a 10% w/w gel and the control gel
base (an oil in water gel comprising xanthan gum
hydrocolloid with polyacrylamide minus the active
pharmaceutical ingredient) [supplied by St Mary’s
Pharmaceutical Unit (SMPU, Cardiff, UK under their
Manufacturer’s Special License (MSL)], gabapentin active
(99.53% was obtained from Lowitt Pharmaceuticals,
Peshawar, Pakistan). Both cisplatin and gabapentin were
dissolved in normal saline.
Animals
Male Sprague Dawley rats (200–250 g) were bred at the
animal house facility in the Department of Pharmacy,
University of Peshawar, Peshawar, Pakistan. They were
maintained in a 12 h/12 h light/dark cycle at 22 ± 2 °C
with ad libitum access to food and water. The
experimental procedures on animals were performed in
compliance with the UK Animals (Scientific Procedures)
Act 1986 and according to the rules and ethics set forth
by the Institutional Ethical Committee. Approval for the
study was granted from the Ethical Committee of the
Department of Pharmacy, University of Peshawar with
the registration number: 13/EC-15/Pharm. At the end
of experiments, the animals were euthanized by cervical
dislocation under anesthesia (intraperitoneal injection
of a mixture of xylazine at 10 mg/kg and ketamine at
100 mg/kg).
Cisplatin induced neuropathy treatment schedule
Cisplatin-induced neuropathic nociception was estab-
lished using four cisplatin intraperitoneal injections (3.0
mg/kg) each at weekly intervals as previously reported
[21]. Before each cisplatin injection, hyperhydration was
induced by the subcutaneous injection of 2.0 mL normal
saline in order to avoid cisplatin associated nephrotox-
icity. The hydration strategy has been shown to
significantly lower the incidence of cisplatin-induced
renal damage [44] and has been recommended for
preventing cisplatin-induced nephrotoxicity before and
after administration of cisplatin [45, 46].
To assess the effect of topical gabapentin, a uniform
quantity of 10% gabapentin gel (1.0 mg/cm2) (GBP-10%)
was applied topically three times daily on the plantar
surface of both hind paws [43]. An equivalent amount of
control gel (1.0 mg/cm2) (CG) was also applied on the
hind paws of the control animals. In the systemic study,
gabapentin was administered intraperitoneally once daily
at a dose of 75 mg/kg (GBP-75) [33]. Moreover, as a
negative control, a group of cisplatin injected animals
were systemically administered (i.p.) once daily with
equal volume of saline. The animals were randomly
assigned to the following treatment groups (n = 6) and
the study was continued for 28 days:
Group 1: Saline (1.0 mL/kg, i.p.)
Group 2: Cisplatin (3.0 mg/kg/week, i.p.)
Group 3: Saline (1.0 mL/kg, i.p.) + Cisplatin (3.0 mg/kg/
week, i.p.)
Group 4: GBP-10% (1.0 mg/cm2/× 3/day) + Cisplatin
(3.0 mg/kg/week, i.p.)
Group 5: GBP-75 (75 mg/kg/day, i.p.) + Cisplatin (3.0
mg/kg/week, i.p.)
Group 6: CG (1.0 mg/cm2/× 3/day) + Cisplatin (3.0 mg/
kg/week, i.p.)
Group 7: GBP-10% (1.0 mg/cm2/× 3/day)
Group 8: GBP-75 (75 mg/kg/day, i.p.)
Group 9: CG (1.0 mg/cm2/× 3/day)
Neuropathic paradigm of static allodynia
The mechanical allodynia expression in the hind paws
after dosing with cisplatin was evaluated using von Frey
filaments (Stoelting, Wood Dale, Illinois, USA). Each
filament was applied to the mid-plantar surface until it
buckles [47] and the nociceptive response was measured
as the paw withdrawal threshold (PWT, g). The static
allodynia paradigm was determined at the end of each
week [13, 48].
Neuropathic paradigm of heat hypoalgesia
The expression of cisplatin associated heat hypoalgesia
was assessed in rat hind paws using a digital hot-plate
apparatus (Harvard apparatus, USA). The hot-plate was
thermostatically maintained at 52.0 ± 0.2 °C and the
escape phenomenon was measured in seconds as jump-
ing or hind paw lifting/licking. A cut-off time limit of 40
s was selected in order to avoid tissue injury. Each
response latency was quantified as the paw withdrawal
latency (PWL). Neuropathic heat-hypoalgesia was
measured at the end of each week of the 4 weeks’ para-
digm [13].
Motor coordination and balance
The motor coordination and the central side-effects pro-
pensity was assessed using the rotarod paradigm. Each
animal was placed on a variable speed rotating rod and
the endurance latency was determined in seconds on
days 7, 14, 21 and 28 after 60–80min post topical or
systemic treatment [43]. The gait impairment was
evaluated using footprint analysis. The overlap between
forepaw and hind paw placement was quantified 60–80
min post topical or systemic treatment [43].
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Data analysis
The data were presented as mean ± standard error of the
mean (SEM) and were analyzed by two-sample t-test (sa-
line and cisplatin only groups) or by two-way repeated
measures analysis of variance (ANOVA) followed by post
hoc Bonferroni’s test (cisplatin injected groups treated
with saline and systemic or topical gabapentin). The
neuropathic paradigms of paw withdrawal thresholds and
latencies were converted into percentage anti-allodynia
and heat anti-hypoalgesia, respectively. Moreover, the
rotarod dismount latencies and the paw overlap distance
were respectively transformed into motor incoordination
and paw displacement indices as previously reported [13].
All statistical analyses were conducted using GraphPad
Prism 5 (GraphPad Software Inc. San Diego CA, USA). A
value of P < 0.05 was considered as significant.
Results
Topical gabapentin gel de-escalation of cisplatin
neuropathic allodynia
Single weekly administration of cisplatin was associated
with a marked decrease in the threshold to perceive noci-
ception evoked by non-nociceptive static stimuli. This was
evident from a tapering decline of nociceptive thresholds
with cumulative cisplatin doses. The application of graded
von Frey filaments against the mid-plantar surface of the
hind paws elicited a response observed as a brisk paw
withdrawal. This aberrant behavior was detected as a
significant decrease in the applied force in grams and was
primarily noted after the first week of cisplatin injection
[day 7: 9.97 g; t(5) = 2.760, P = 0.0398] as compared to that
of the saline treated controls (14.33 g on day 7). After the
first week, a temporal decrement in threshold was appar-
ent as a graded reduction in nociception to the normally
non-nociceptive stimulus. Thus a significant decrease in
the threshold paw withdrawal response was expressed to
the increasing static pressure of von Frey filaments in the
cisplatin dosed animals in the 2nd week [day 14: 7.28 g;
t(5) = 5.602, P = 0.0025] and 3rd week of the study [day
21: 5.82 g; t(5) = 12.34, P < 0.0001]. A fully expressed static
allodynia emerged after the last cisplatin injection (4th
week) during which the reduction in the nociceptive
threshold was fully discernable [day 28: 3.68 g; t(5) =
26.25, P < 0.0001]. Similarly, the saline treated cisplatin an-
imals also presented with a similar manifestation of static
hind paw allodynia after week 1 [day 7: 10.3 g; t(5) = 2.722,
P = 0.0417], week 2 [day 14: 7.75 g; t(5) = 4.853, P =
0.0047], week 3 [day 21: 5.38 g; t(5) = 9.597, P = 0.0002],
and week 4 [day 28: 3.76 g; t(5) = 23.73, P < 0.0001] as
compared to the respective thresholds of the saline treated
non-cisplatin dosed control animals (14.66 g on day 14,
14.42 g on day 21, and 14.88 g on day 28) (Fig. 1 and
Additional file 1: Table S1).
Treatment with topical as well as systemic gabapentin
produced a beneficial antinociceptive action against the
expression of cisplatin induced hind paw allodynia
[time = (F (4, 200) = 52.75, P < 0.0001), treatment = (F (8,
200) = 65.01, P < 0.0001), interaction = (F (32, 200) =
5.87, P < 0.0001)]. When the gel formulation of gabapen-
tin (10%) was applied topically three times daily on the
hind paw plantar surface, an elevated paw withdrawal
threshold was observed which reversed the cisplatin
induced progressive decline in the nociceptive threshold.
It was notable that the allodynia offsetting effect of gaba-
pentin gel was not evident after 14 days (2nd injection of
cisplatin). However, a distinguishable increase in the
diminished neuropathic threshold force was noticeable
after the 3rd cisplatin injection when a significant
Fig. 1 Effect of topical gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic gabapentin at 75mg/kg (GBP-75, i.p.) on the expression
of cisplatin induced static allodynia [diminished von Frey filament threshold pressure (paw withdrawal threshold; PWT in g)] in hind paws after weekly
intraperitoneal injection of cisplatin at 3.0 mg/kg (Cis-3) for four consecutive weeks in rats. Each symbol represents the mean PWT in g ± SEM. #P < 0.05,
##P < 0.01, ###P < 0.001 as compared to the saline (Sal) alone treated control group, *P < 0.05, **P < 0.01, ***P < 0.001 as compared to the cisplatin plus
saline treated group, two-way repeated measures ANOVA followed by post hoc Bonferroni’s analysis; n = 6 rats per group
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increase in PWT (day 21: 9.01 g, P < 0.05) was observed
as compared to the cisplatin untreated animal group.
This effect became more pronounced after the 4th and
last cisplatin injection (day 28: 7.65 g, P < 0.01). The con-
current topical application of the control gel was devoid
of any cisplatin allodynia modifying action throughout
the four-week testing paradigm (6.79–4.86 g on days 14–
21). Systemic administration of gabapentin (75 mg/kg)
reversed the cisplatin-downgraded threshold and it was
more effective in this respect than the topical route. The
increase in perceived static force was found to be signifi-
cant after the second cisplatin injection (11.12 g, P <
0.01) and this was maintained for the subsequent study
period i.e. after the 3rd week (10.06 g, P < 0.001) and 4th
week (9.67 g, P < 0.001) of the cisplatin injection protocol
(Fig. 1 and Additional file 1: Table S1).
The antinociceptive activity of topical and systemic
gabapentin against cisplatin neuropathic allodynia was
substantiated by our findings [time = (F (3, 120) = 0.94,
P = 0.6913), treatment = (F (6, 120) = 65.10, P < 0.0001),
interaction = (F (18, 120) = 0.94, P = 0.5297)]. Thus, a sig-
nificant increase in percentage antinociception was
afforded by topical gabapentin on day 21 (37.51%, P <
0.05) and day 28 (38.08%, P < 0.05), as compared to the
cisplatin administered saline treated group (− 4.89 and
0.79%). The percentage protection provided by systemic
gabapentin was found to be greater, disclosing a signifi-
cant increase on test day 14 (48.78%, P < 0.05), day 21
(51.99%, P < 0.001), and day 28 (53.27%, P < 0.01). The
inefficacy of the control gel in attenuating the neuro-
pathic symptoms was endorsed by non-significant
intergroup anti-allodynic differences compared to the
saline treated cisplatin animals (16.69 and 5.47% on days
21–28). No deviant threshold changes indicative of any
allodynic tendency were observed in the groups of ani-
mals treated alone with gabapentin 10% gel, control gel
and systemic gabapentin at 75 mg/kg. Additionally, the
responses of these groups were found to be significantly
different from the cisplatin untreated or saline-treated
animals in terms of the pressure required to elicit a
response (P < 0.001) or percentage protection (P < 0.001).
Topical gabapentin gel alleviation of cisplatin
neuropathic hypoalgesia
Intraperitoneal administration of cisplatin impaired the
perception of the heat stimulus on the hot plate. This
cisplatin induced neuropathic thermal hypoalgesia
followed a slower course of onset because there was no
significant increase in paw withdrawal after the second
weekly cisplatin dose [day 14: 21.50 s; t(5) = 2.260, P =
0.0734]. However, following the 3rd injection of cis-
platin, a significant difference in the thermal withdrawal
latency was noted between the cisplatin administered
animals and the saline treated control group. Hence,
there was a marked increase in the paw thermal thresh-
old on protocol day 21 [26.67 s; t(5) = 3.932, P = 0.0110]
and this thermal hypoalgesia was maintained with an
increased intensity after the last cisplatin injection i.e. at
the end of the 4th week [day 28: 29.67 s; t(5) = 7.340,
P = 0.0007]. The cisplatin treated group which received
saline, also exhibited a similar thermal hypoalgesia
expression profile with an increased hot-plate latency
being detected after week 2 [day 14: 21.67 s; t(5) = 2.769,
P = 0.0394] and this effect was even more pronounced at
the end of week 3 [day 21: 25.83 s; t(5) = 3.466, P =
0.0179], and week 4 [day 28: 29.17 s; t(5) = 3.720, P =
0.0137] of the cisplatin injection protocol (Fig. 2 and
Additional file 1: Table S2).
Fig. 2 Effect of topical gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic gabapentin at 75mg/kg (GBP-75, i.p.) on the expression
of cisplatin induced heat hypoalgesia [increased nociceptive response latency to heat stimulus in the hot-plate paradigm (paw withdrawal latency;
PWL in s)] in bilateral hind paws after weekly intraperitoneal injection of cisplatin at 3.0 mg/kg (Cis-3) for four consecutive weeks. Each symbol
represents the mean PWL in s ± SEM. #P < 0.05, ###P < 0.001 as compared to the saline (Sal) treated controls, *P < 0.05, **P < 0.01, as compared to the
cisplatin plus saline treated animal group, two-way repeated measures ANOVA followed by post hoc Bonferroni’s analysis; n = 6 rats per group
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The three times daily topical application or daily sys-
temic intraperitoneal administration of gabapentin offset
the expression of thermal hypoalgesia in the hind paws
[time = (F (4, 200) = 33.10, P < 0.0001), treatment = (F (8,
200) = 17.17, P < 0.0001), interaction = (F (32, 200) = 2.42,
P = 0.0001)]. Topical gabapentin (10%) gel reversed the el-
evated neuropathic thermal paw reaction latencies by the
end of the third week (day 21: 21.83 s) and this was more
marked at the end of the fourth week (day 28: 24.33 s, P <
0.05). There was no significant change in paw reaction la-
tencies in the control gel treated animals compared to the
cisplatin alone group, but systemic gabapentin did reduce
withdrawal responses associated with cisplatin treatment.
Accordingly, a significant attenuation of the cisplatin
prolonged PWL was apparent by test day 21 of the para-
digm (21.66 s, P < 0.05) and day 28 (22.50 s, P < 0.01). In
contrast and somewhat predictably, the group of animals
treated with saline was not found to induce any detectable
alteration of cisplatin heat hypoalgesia at any time during
the whole period of the four-week protocol (Fig. 2 and
Additional file 1: Table S2).
The anti-neuropathic hypoalgesic efficacy underlying
the topical and systemic gabapentin hot-plate response
was confirmed by our findings [time = (F (3, 120) = 4.54,
P = 0.0139), treatment = (F (6, 120) = 20.54, P < 0.0001),
interaction = (F (18, 120) = 2.51, P = 0.0016)]. Protection
provided by the gabapentin gel formulation was more
clear-cut after protocol week 4 when the latency differ-
ence achieved statistical significance (day 28: -19.93%,
P < 0.01). Likewise, systemic gabapentin also produced a
similar heat-hypoalgesia attenuating trend by producing
a non-significant percentage neuropathic hypoalgesia
aberration on day 21 (− 13.84%) followed by a significant
suppressive effect on study day 28 (− 26.02%, P < 0.001)
whereas the control gel was inactive throughout.
Motor discoordination induced by systemic but not
topical gabapentin
Considerable changes in motor coordination and loco-
motor gait were observed in the rotarod and footprint
analysis paradigms after administration of cisplatin and
gabapentin [time = (F (4, 200) = 32.14, P < 0.0001), treat-
ment = (F (8, 200) = 101.33, P < 0.0001), interaction = (F
(32, 200) = 6.89, P < 0.0001)]. A progressive decline in
endurance latency on the accelerating rotarod was
observed in the groups of animals administered cisplatin
either alone or along with saline. There was no signifi-
cant reduction noted at the end of week 2 (day 14:
177.6 s) and week 3 (day 21: 170.6 s), but a significant
deterioration in endurance latency after the final cis-
platin injection i.e. week 4 (165.5 s, P < 0.05). A marked
impairment of motor coordination was detected in the
cisplatin plus systemic gabapentin (75 mg/kg) treated
animal group as well as those administered systemic
gabapentin alone. Thus, the cisplatin dosed animals co-
treated with systemic gabapentin exhibited a significant
decrease in rotarod endurance latency on paradigm day
7 (98.66 s, P < 0.001), day 14 (92.66 s, P < 0.001), day 21
(93.50 s, P < 0.001) as well as day 28 (90.16, P < 0.001).
Similarly, treatment with systemic gabapentin by itself was
also associated with a significant decrease in dismount la-
tency on day 7 (106.50s, P < 0.001), day 14 (109.50s, P <
0.001), day 21 (104.16 s, P < 0.001) and day 28 (106.66 s,
P < 0.001), in comparison with corresponding saline
controls (Fig. 3 and Additional file 1: Table S3).
The rotarod endurance latency [time = (F (3, 160) =
2.40, P = 0.0981), treatment = (F (8, 160) = 336.30.43, P <
0.0001), interaction = (F (24, 160) = 1.18, P = 0.2694)]
also disclosed a significant motor impairment in the ani-
mals administered cisplatin on its own (day 14: 10.43%,
P < 0.05; day 21: 12.53%, P < 0.05; day 28: 15.52%, P <
Fig. 3 Effect of topical gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic gabapentin at 75 mg/kg (GBP-75, i.p.) on rotarod
performance after weekly i.p. injection of cisplatin (Cis) at 3.0 mg/kg (Cis-3) for four consecutive weeks in rats. Each symbol represents the mean
endurance latency in s ± SEM, 1 h post treatment. *P < 0.01, ***P < 0.001 as compared to the saline (Sal) treated control group, two-way repeated
measures ANOVA followed by post hoc Bonferroni’s analysis; n = 6 rats per group
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0.001), and in the group given cisplatin plus injected sa-
line (day 14: 10.33%, P < 0.05; day 21:12.66%, P < 0.05;
day 28: 14.10%, P < 0.01) as compared to the saline alone
treated control group (1.62, 3.72, 2.71% during days 14–
28). Motor discoordination was also exhibited in the
groups of cisplatin administered animals treated with
topical gabapentin gel (9.61, 12.8%, P < 0.05 during days
14–21; and 16.8%, P < 0.001 on day 28) as well as the
control gel (10.80%, P < 0.05 on day 14; 14.30%, P < 0.01
on day 21; and 15.88%, P < 0.001 on day 28). An exten-
sive deficit in motor coordination (P < 0.001) was created
by systemic gabapentin treatment on its own as well as
in combination with cisplatin (day 7: 49.83 and 46.09%,
day 14: 53.77 and 45.03%, day 21: 52.27 and 47.07%, and
day 28: 54.53 and 46.20%), as compared to saline treated
controls.
Footprint pattern analysis revealed that the animals
systemically treated with gabapentin expressed a marked
disturbance of locomotor gait and this was thought to
be derived from a disruption of balance [time = (F (4,
200) = 8.66, P = 0.0002), treatment = (F (8, 200) = 47.42,
P < 0.0001), interaction = (F (32, 200) = 3.31, P < 0.0001)].
This major unwanted effect was recorded as a significant
increase (P < 0.001) in the overlap distance between the
forepaw and hind paw placements after treatment with
gabapentin in the cisplatin injected animals in addition
to those administered gabapentin by itself during the
entire study period i.e. day 7 (1.44 cm and 1.41 cm), day
14 (1.44 cm and 1.39 cm), day 21 (1.47 cm and 1.42 cm),
and day 28 (1.48 cm and 1.42 cm) as compared to the
saline controls on the appropriate corresponding days
(0.97 cm on day 7, 0.95 cm on day 14, 0.96 cm on day
21, and 0.98 cm on day 28). Additionally, there was no
significant disturbance of locomotor gait produced in
the cisplatin administered animals or by saline treatment
alone, particularly at the end of week 3 (1.09 cm and
1.07 cm on day 21) and week 4 (1.14 cm and 1.13 cm
on day 28) as shown in Fig. 4 and Additional file 1:
Table S4.
The percentage foot displacement [time = (F (3, 160) =
0.97, P = 0.4260), treatment = (F (8, 160) = 241.26, P <
0.0001), interaction = (F (24, 160) = 1.63, P = 0.0406)]
further substantiated the significant degree of walking
impairment (P < 0.001) after treatment with systemic
gabapentin (75 mg/kg) by itself or in combination with
cisplatin on protocol day 7 (− 48.82% and − 45.41%), day
14 (− 49.43% and − 44.95%), day 21 (− 52.43% and −
46.73%), and day 28 (− 51.07% and − 45.75%), as
compared to that of the respective saline group (− 1.03,
2.11, 1.01 and 0.51%). In addition to this, a significant
impairment of balance was also observed in the cisplatin
untreated and saline treated animals (day 21: -12.76%,
P < 0.001 and − 11.40%, P < 0.01; and P < 0.001 on day
28: − 16.50% and − 15.78%) as compared to the saline
controls. There was no significant distortion of gait by
cisplatin, topical gabapentin or control gel treatment up
to protocol day 14 though there was subsequent mild
gait disturbance by cisplatin and topical gabapentin
which attained statistical significance (P < 0.01 on day
21: − 10.34% and − 11.46%, and P < 0.001 on day 28: −
15.52% and − 13.48%). Moreover, topical gabapentin and
the control gel were not associated with any variation in
foot placement during the entire study.
Discussion
The present study evaluated the antinociceptive effect-
iveness of topical gabapentin gel in relation to systemic
gabapentin in a well-established cisplatin rat model of
Fig. 4 Effect of topical gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic gabapentin at 75 mg/kg (GBP-75, i.p.) on footprint
pattern analysis after weekly i.p. injection of cisplatin (Cis) at 3.0 mg/kg (Cis-3) for four consecutive weeks in rats. The measured parameter was
expressed as the overlap distance between the forepaw and hind paw placements, 1 h post treatment. Each symbol represents the mean paw
overlap in cm ± SEM. ***P < 0.001 as compared to the saline (Sal) treated control group, two-way repeated measures ANOVA followed by post hoc
Bonferroni’s analysis; n = 6 rats per group
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CIPN. Cisplatin administration has been reported to be
associated with the development of mechanical allodynia
and hyperalgesia, cold thermal allodynia and hyperalge-
sia, as well as heat thermal hypoalgesia in rats [21, 49].
Although in humans, most anticancer chemotherapeutic
drugs are given intravenously, especially by continuous
intravenous infusion, in this study, the peripheral neuro-
pathic pain conditions associated with cisplatin was
established by intraperitoneal injection of cisplatin. It
has been observed in rats that the cisplatin levels in
intra-abdominal tumor tissues following the use of the
intraperitoneal route are greater than those after the
intravenous route. In addition, concentrations of cis-
platin in serum are also sufficiently greater with pro-
longed drug elimination after the use of the
intraperitoneal route [50]. In another study, cisplatin
injected intraperitoneally, significantly prolonged the
lifespan median by 88% and in fact, it was ineffective
when injected intravenously, in experimental rats with
disseminated ovarian cancer [51]. Moreover, it has been
confirmed clinically that intraperitoneal chemotherapy is
feasible with acceptable toxicity and that intraperitoneal
compared with intravenous cisplatin combination ther-
apy yields a slight improvement in progression-free
survival and overall survival of optimally cytoreduced
advanced ovarian cancer [52].
This study has shown that, similar to systemic treat-
ment, daily topical application of gabapentin strongly
attenuated cisplatin associated neuropathic allodynia and
heat-hypoalgesia. Topical application of 10% gabapentin
caused a substantial reduction of pain in patients
afflicted with different types of neuropathy [53, 54].
Compounded formulations containing gabapentin (6%)
in combination with other drugs are effective in relieving
pain conditions in > 75% of patients with neuropathies
[55]. Moreover, topical 10% gabapentin has also been
shown to allay both static and dynamic allodynia as well
as vulvodynia in an animal model of streptozotocin
induced polyneuropathy [33]. It also produced effective-
ness against chronic constriction injury of the sciatic
nerve induced tactile as well as cold-allodynia, along
with heat and mechanical hyperalgesia in a rodent model
of mononeuropathy [43]. Hence, these studies corrobo-
rated the antinociceptive efficacy of the topical formula-
tion of gabapentin in neuropathic pain.
The value of the skin as a target for topical as well as
the systemic medications to treat neuropathic pain is
supported by studies demonstrating the importance of
skin as a neuroimmunocutaneous system [32, 56].
Topical formulations traverse epidermal tissue and in-
crease the nociceptive threshold by stabilizing the mem-
branes of specific nociceptors including α2-adrenergic
receptors, NMDA receptors, TRPVI receptors, and
sodium channels [35]. Furthermore, the different types
of non-neural cells in the skin also contain a variety of
ion channels like those for Na+ and pharmacological
receptors such as vanilloid, neurokinin, serotonin, can-
nabinoid, NMDA and GABAA receptors that may be
modified by topical drugs to regulate communication
with dermal neurons to elicit robust analgesia [32]. It is
decidedly possible therefore; that these mechanisms
might be responsible for the antinociceptive effect of
topical gabapentin in cisplatin induced neuropathic
nociception.
In this study, a convincing relieving outcome on cis-
platin-induced heat hypoalgesia was perceptible for daily
systemic treatment with gabapentin only on expression
days 21 and 28. This lesser efficacy of systemic gabapentin
on cisplatin-induced heat hypoalgesia can be attributed to
the inherent antinociceptive propensity of gabapentin.
Systemic gabapentin has a central antinociceptive activity
and is able to attenuate acute phasic thermal nociception
[57, 58]. The pharmacological effects of gabapentin oper-
ate by: increasing GABA levels [59], acting as a non-
NMDA receptor antagonist [60, 61], inhibiting voltage
gated calcium channels [62, 63], inhibiting anterograde
axoplasmic transport of α2δ-1 subunits, decreasing the re-
lease of glutamate, CGRP and substance P, decreasing
microglial activation, reducing the number of astrocytes
and inhibiting protein kinase C as well as TRP ion chan-
nels [64].
Systemic treatment with gabapentin in clinical doses
adjusted for neuropathic pain has been associated with
somnolence, dizziness, ataxia, and fatigue [28]. This can
be further endorsed by the withdrawal rate of patients
due to such adverse effects in clinical studies on
systemic gabapentin efficacy in CIPN [23]. In this study,
using different testing paradigms, systemic gabapentin
produced only a transient increase in locomotion but
induced considerable impairment of motor coordination.
Ostensibly, topical gabapentin gel has not been associ-
ated with any of these unwanted systemic effects. The
occurrence of side effects, along with therapy specific
precautions and contraindications has limited the
clinical utility of pharmacological treatments and only <
50% of neuropathic patients actually show any improve-
ment in their pain states [30]. Although the systemic
pharmacotherapy of painful neuropathy is currently the
standard treatment approach, given the concomitant
side effects, limited response rates, and potential for
drug interactions, the use of the topical route may be a
useful option for the effective as well as safe manage-
ment of neuropathic pain [65, 66].
Conclusion
The topical and systemic administration of gabapentin di-
minished chemotherapy associated peripheral neuropathic-
like pain. There was as a significant attenuation of
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neuropathic allodynia and heat-hypoalgesia observed in a
refined cisplatin rodent model of CIPN. The findings
suggest that gabapentin has the potential to address the
unmet pain reducing needs of patients diagnosed with
chronic neuropathic pain undergoing treatment with che-
motherapeutic drugs like cisplatin. In addition, it may also
provide an alternative option for alleviation of neuropathic
pain in the form of a compounded topical formulation if
systemic medications are stopped due to intolerable side
effects. Consequently, this delivery route for gabapentin
may also be utilized as part of a comprehensive multi-mode
pain management system. Definitive confirmation of this
proposition can only be achieved if tested clinically in
cancer patients suffering neuropathic pain.
Additional file
Additional file 1: Table S1. Effect of per se treated topical gabapentin
10% gel (GBP-10%), topical control gel (CG) and systemic gabapentin at
75 mg/kg (GBP-75, i.p.) during the expression of cisplatin-induced static
allodynia [diminished von Frey filament threshold pressure (paw
withdrawal threshold; PWT in g)] in hind paws after weekly
intraperitoneal injection of cisplatin at 3.0 mg/kg (Cis-3) for four
consecutive weeks in rats. Table S2. Effect of per se treated topical
gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic
gabapentin at 75 mg/kg (GBP-75, i.p.) during the expression of cisplatin-
induced heat hypoalgesia [increased nociceptive response latency to
heat stimulus in the hot-plate paradigm (paw withdrawal latency; PWL in
s)] in bilateral hind paws after weekly intraperitoneal injection of cisplatin
at 3.0 mg/kg (Cis-3) for four consecutive weeks in rats. Table S3. Effect of
per se treated topical gabapentin 10% gel (GBP-10%), topical control gel
(CG) and systemic gabapentin at 75 mg/kg (GBP-75, i.p.) on rotarod
performance during neuropathic nociception induced after weekly
intraperitoneal injection of cisplatin (Cis) at 3.0 mg/kg (Cis-3) for four
consecutive weeks in rats. Table S4. Effect of per se treated topical
gabapentin 10% gel (GBP-10%), topical control gel (CG) and systemic
gabapentin at 75 mg/kg (GBP-75, i.p.) on footprint pattern analysis during
neuropathic nociception induced after weekly intraperitoneal injection of
cisplatin (Cis) at 3.0 mg/kg (Cis-3) for four consecutive weeks in rats. The
measured parameter was expressed as the overlap distance between the
forepaw and hind paw placements, 1 h post treatment. (DOCX 20 kb)
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